Skip to main content
. 2023 Dec 15;13:37. doi: 10.25259/JCIS_66_2023

Supplementary Table 1:

Treatment characteristics of 57 RCC.

RAPN, n= 18 Cryoablation, n= 39A
Anesthesia, n(%)
  Sedation N/A 37 (97.4)
  GA 18 (100) 1 (2.6)
Type of cryoprobes
  Force N/A 26 (68.4)
  Rod 2 (5.3)
  Pearl 9 (23.7)
  Mix 1 (2.6)
Number of probes per tumor, n(%)
  2 N/A 12 (31.6)
  3 14 (36.8)
  4 7 (18.4)
  5 3 (7.9)
  6 1 (2.6)
  7 1 (2.6)
Hydro displacement, n(%)
  Yes 27 (71.1)
  No 11 (28.9)
Dose, mL
  Median (IQR) N/A 320 (280–510)
  Mean (±SD) 457.9 (308.9)
  Range 122–1,360
Knife time, min
  Median (IQR) 175 (160–214) 60 (49.3–83.0)
  Mean (±SD) 181.1 (46.3) 68.8 (24.5)
  Range 79–269 38–138
WIT, min
  Median (IQR) 17.5 (12–20) N/A
  Mean (±SD) 17.3 (5.6)
  Range 11–30
Blood loss, mL
  Median (IQR) 100 (100–237.5) N/A
  Mean (±SD) 183.3 (158.1)
  Range 0–600
Blood transfusion, n(%)
  Yes 1 (5.3) N/A
  No 18 (94.3)

RAPN: Robot-assisted partial nephrectomy, RCC: Renal cell carcinoma, GA: General anesthesia, WIT: Warm ischemia time, N/A: Not applicable, IQR: Interquartile range, SD: Standard deviation. AOne patient underwent cryoablation of two RCC